VIVOVERSE, LLC
Biotech · Private
High-throughput automated imaging platform (vivoChip) for screening drug efficacy and toxicity using C. elegans model organisms
- Grants
- $5.6M
- 12 awards
- Sector median: 1
- Raised
- —
- No Form D on record
- Contracts
- —
- No federal contracts on record
- Patents
- 1
- 0 granted · 1 pending
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓20182019202020212022202320242025
| Date | Event | Source | Amount |
|---|---|---|---|
| Federal grant | Department of Health and Human Services · Phase I · A multiwell plate format microfluidic immobilization chip for high-content imaging of whole animals | $218,367 | |
| Federal grant | Department of Health and Human Services · Phase I · A multiwell plate format microfluidic immobilization chip for high-content imaging of whole animals | $55,000 | |
| Federal grant | Department of Health and Human Services · Phase I · A Large-Scale Microfluidics Imaging Platform for High-Throughput Toxicity Testing using Canine Intestinal Organoids | $222,780 | |
| Federal grant | Department of Health and Human Services · Phase II · A Multiwell Plate Format Microfluidic Immobilization Chip for High-Content Imaging of Whole Animals for in vivoNeurotoxicology Testing | $749,858 | |
| Federal grant | Department of Health and Human Services · Phase II · A Multiwell Plate Format Microfluidic Immobilization Chip for High-Content Imaging of Whole Animals for in vivoNeurotoxicology Testing | $749,956 | |
| Federal grant | Department of Health and Human Services · Phase I · The Next-Generation Developmental and Reproductive Toxicology (DART) Assay using High-Content Analysis of Genetically Diverse C. elegans Populations | $253,681 | |
| Federal grant | Department of Health and Human Services · Phase II · A Multiwell Plate Format Microfluidic Immobilization Chip for High-Content Imaging of Whole Animals for in vivoNeurotoxicology Testing | $749,890 | |
| Federal grant | Department of Health and Human Services · Phase II · The Next-Generation Developmental and Reproductive Toxicology (DART) Assay using High-Content Analysis of Genetically Diverse C. elegans Populations | $996,687 | |
| Federal grant | Department of Health and Human Services · Phase I · High-Content in vivo DNT Test Batteries using Cell-Specific Characterization of the Neurodevelopment and Synaptogenesis in C. elegans as NAMs | $287,021 | |
| Federal grant | Department of Agriculture · **awards Issued Prior To January 20, 2025, Were Funded Under Previous Administrations And May Not Reflect The Priorities And Policies Of The Current Administration.** The Field Of Food Science Is Growing Rapidly To Develop New Substances With Added Nutritional Values And Discover New Therapeutic Benefits Such As A Source Of Natural Antioxidants, Health-promoting Materials, Nutraceuticals, And Potential Functional Foods. Identifying And Quantifying Nutritional Benefits In Food Ingredients And Eva | $175,000 | |
| Federal grant | Department of Health and Human Services · Phase II · The Next-Generation Developmental and Reproductive Toxicology (DART) Assay using High-Content Analysis of Genetically Diverse C. elegans Populations | $841,749 | |
| Federal grant | Department of Health and Human Services · Phase I · High-content study to analyze the nutritional value of natural products for healthy aging | $306,793 |
Federal grant · SBIR/STTR
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 2502 | Celmatix Inc. | — | $20M |
| 2503 | Exciva | — | — |
| 2504 | GYRE THERAPEUTICS, INC. | — | $5.0M |
| 2505 | VIVOVERSE, LLC | — | — |
| 2506 | Kamau Therapeutics, Inc. | — | $5.0M |
| 2507 | CONFLUENCE LIFE SCIENCES, INC. | — | $5.7M |
| 2508 | Panorama Medicine Inc | — | $4.7M |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Patents
- Method And Compositions For Analyzing Toxicity In Organismsapplication
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.